KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Gross Margin (2016 - 2025)

Neogenomics (NEO) has disclosed Gross Margin for 16 consecutive years, with 43.83% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 109.0% year-over-year to 43.83%, compared with a TTM value of 43.21% through Dec 2025, down 71.0%, and an annual FY2025 reading of 43.21%, down 71.0% over the prior year.
  • Gross Margin was 43.83% for Q4 2025 at Neogenomics, up from 42.84% in the prior quarter.
  • Across five years, Gross Margin topped out at 44.92% in Q4 2024 and bottomed at 32.63% in Q1 2022.
  • Average Gross Margin over 5 years is 40.73%, with a median of 41.45% recorded in 2023.
  • Peak annual rise in Gross Margin hit 1133bps in 2021, while the deepest fall reached -960bps in 2021.
  • Year by year, Gross Margin stood at 35.99% in 2021, then increased by 14bps to 40.97% in 2022, then rose by 6bps to 43.45% in 2023, then grew by 3bps to 44.92% in 2024, then fell by -2bps to 43.83% in 2025.
  • Business Quant data shows Gross Margin for NEO at 43.83% in Q4 2025, 42.84% in Q3 2025, and 42.61% in Q2 2025.